PUBLISHER: DelveInsight | PRODUCT CODE: 1553388
PUBLISHER: DelveInsight | PRODUCT CODE: 1553388
DelveInsight's "Adrenocortical Carcinoma (ACC) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Adrenocortical Carcinoma (ACC), historical and forecasted epidemiology and the Adrenocortical Carcinoma (ACC) market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Adrenocortical Carcinoma (ACC) market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Adrenocortical Carcinoma (ACC) market size from 2020 to 2034. The report also covers current Adrenocortical Carcinoma (ACC) treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2020-2034
Adrenocortical Carcinoma (ACC) Overview
ACC is a rare and aggressive cancer originating in the adrenal cortex above the kidneys. Risk factors include genetic syndromes like Li-Fraumeni and Beckwith-Wiedemann, inherited mutations, family history of adrenal tumors, and radiation exposure.
ACC progresses through stages based on tumor size and metastasis. Early stages involve confined tumors, while later stages may see invasion into nearby tissues or distant spread to organs like the liver, lungs, or bones. Staging guides treatment strategies by assessing disease extent.
Adrenocortical Carcinoma (ACC) Diagnosis
ACC diagnosis entails a comprehensive approach, starting with medical history review and physical examination to detect adrenal gland abnormalities. Imaging tests like CT, MRI, and PET scans visualize tumors and their extent, while blood and urine tests measure hormone levels and metabolic markers. Biopsies, though definitive, carry risk and aren't always performed. Genetic testing may be advised, particularly with familial history. Staging scans inform treatment decisions, often involving surgery, chemotherapy, radiation, or targeted therapy, supported by multidisciplinary healthcare teams.
Adrenocortical Carcinoma (ACC) Treatment
Treatment options for adrenocortical carcinoma (ACC) include surgery, radiation therapy, chemotherapy, and ongoing investigation into new treatments like immunotherapy and targeted therapy through clinical trials. Surgery, particularly adrenalectomy, is common for removing affected adrenal glands, potentially along with nearby tissues. Radiation therapy uses high-energy x-rays to kill cancer cells, while chemotherapy halts their growth with drugs. Immunotherapy engages the patient's immune system, and targeted therapy attacks specific cancer cells.
As the market is derived using the patient-based model, the Adrenocortical Carcinoma (ACC) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Incident Cases of ACC, Stage-specific Incident Cases of ACC, Gender-specific Incident Cases of ACC, and Age-specific Incident Cases of ACC in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.
As per DelveInsight's estimations, the total incident cases of ACC in the 7MM were approximately 12 hundred in 2023 and are projected to increase during the forecast period, owing to the Increasing incidence trends over decades and advancements in diagnostic tools contribute to a better understanding and identification of this rare malignancy.
The drug chapter segment of the Adrenocortical Carcinoma (ACC) report encloses a detailed analysis of Adrenocortical Carcinoma (ACC) marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands Adrenocortical Carcinoma (ACC) clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Marketed Drugs
LYSODREN (Mitotane): HRA Pharma/Bristol-Myers Squibb
The adrenal cytotoxic agent mitotane (LYSODREN) has a central role in the systemic treatment of adrenocortical carcinoma (ACC), a rare and aggressive cancer of the adrenal glands. Mitotane has been evaluated and used for more than 60 years and, to date, is the only drug specifically approved for the treatment of ACC. Although ACC continues to be associated with a poor prognosis, mitotane has been shown to provide clinically significant benefit in a good proportion of ACC patients treated with the drug, both in advanced disease and adjuvant therapy settings. Approved in 1970 in the US and 2004 in the European Union, LYSODREN is listed among the 'Off-Patent, Off-Exclusivity Drugs without an Approved Generic' as outlined in the Orange Book.
Emerging Drugs
EO2401 + Nivolumab: Enterome/Bristol-Myers Squibb
EO2401, a novel immunotherapy developed by Enterome from their proprietary OncoMimics platform, consists of three synthetic peptides mimicking human Tumor-Associated Antigens: IL13Ra2, BIRC5/Survivin, and FOXM1. These peptides, derived from bacteria, target aggressive cancers like glioblastoma and adrenal tumors with minimal impact on healthy tissues. Nivolumab, an immune checkpoint inhibitor, aids T cell expansion and infiltration into tumors.
Adrenocortical Carcinoma (ACC) has a diverse treatment classification associated with the disease landscape. The management of Adrenocortical Carcinoma (ACC) primarily revolves around the utilization of Adjuvant therapy (Mitotane +- Strepto) as needed.
The market for Adrenocortical Carcinoma (ACC) is expected to experience positive growth with the approval of potential drugs like EO2401 + Nivolumab, and others.
This section focuses on the uptake rate of potential drugs expected to launch in the market during 2020-2034. For example, EO2401 + Nivolumab in the US is expected to be launched by 2026, with a peak share of 60%.
Further detailed analysis of emerging therapies drug uptake in the report...
Adrenocortical Carcinoma (ACC) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Adrenocortical Carcinoma (ACC) emerging therapies.
KOL Views
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Adrenocortical Carcinoma (ACC) evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from University of Michigan, Ann Arbor, MI, US, Interfaith Medical Center, Brooklyn, NY, US, Wurzburg University Hospital, Wurzburg, Germany, Center Leon-Berard, Department of Medical Oncology, Lyon, France, University-Hospital of Padua, Padua, Italy, Catalan Institute of Oncology, Barcelona, Spain, University Hospital of Wales, Cardiff, United Kingdom, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, and others.
Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Adrenocortical Carcinoma (ACC) market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Market Insights
Epidemiology Insights
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
The Adrenocortical Carcinoma (ACC) Epidemiology and Market Insight report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of market dynamics and trends during this timeframe.
The Adrenocortical Carcinoma (ACC) market is quite robust. The major players are Enterome, Corcept Therapeutics, Orphagen Pharmaceuticals, and others which are currently developing drugs for the treatment of Adrenocortical Carcinoma (ACC).
The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as incident cases, treatment costs, revenue generated, and market trends.
The increase in the incident cases of Adrenocortical Carcinoma (ACC) and the launch of emerging therapies are attributed to be the key drivers for increasing Adrenocortical Carcinoma (ACC) market.
Introducing new therapies, advancements in diagnostic techniques, and innovations in treatment approaches can significantly impact the Adrenocortical Carcinoma (ACC) treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.
The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Adrenocortical Carcinoma (ACC) market.
List to be continued in the report....